GPCR (Structure Therapeutics) Tariff Resilience Score: 6/10 (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GPCR Structure Therapeutics Inc GPCR
32 GF Score
Price $50.80
View Full Analysis

What is Structure Therapeutics Tariff Resilience Score?

Structure Therapeutics GPCR +0.70% 32 Tariff Resilience Score is 6 as of Jul. 23, 2026. GuruFocus rates GPCR with a GF Score™ of 32/100. Among 1,370 Biotechnology companies, Structure Therapeutics ranks better than 75.99% on this metric.

Structure Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Structure Therapeutics has Biotech firms like GPCR often have global supply chains but may benefit from tariff exemptions on medical goods. However, dependencies on international suppliers pose moderate risk.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Structure Therapeutics might have Average Resilient.

Structure Therapeutics  (NAS:GPCR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Structure Therapeutics Tariff Resilience Score Related Terms

GPCR vs PBLS, IDYA, ELVN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Structure Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Structure Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Structure Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Structure Therapeutics's Tariff Resilience Score falls into.


GPCR
32GF Score
Structure Therapeutics Inc GPCR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Structure Therapeutics (GPCR) has a Tariff Resilience Score of 6 as of Jul. 23, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Structure Therapeutics ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is Structure Therapeutics' Tariff Resilience Score too high?
Structure Therapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Structure Therapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Structure Therapeutics ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Structure Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Structure Therapeutics' Tariff Resilience Score compare to PBLS and IDYA?
According to the Biotechnology industry distribution chart, Structure Therapeutics ranks #329 out of 1370 companies for Tariff Resilience Score. This places Structure Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Structure Therapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Structure Therapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Structure Therapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Structure Therapeutics stock overvalued right now?
Structure Therapeutics (GPCR) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Structure Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Structure Therapeutics (GPCR), the current Tariff Resilience Score is 6 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Structure Therapeutics Business Description

Address 601 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
32GF Score

Get the complete analysis for GPCR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$50.80
Price